
Immunity Pharma Presents New Data Supporting The Efficacy Of IPL344 In ALS
(MENAFN- PR Newswire) Results from phase 2a trial in ALS patients were published in Muscle and Nerve. Statistically significant 58% to 64% slower ALSFRS-R progression rate in IPL344-treated patients compared to the matched PRO-ACT records. NfL was reduced …